Topic Code
HORIZON-HLTH-2026-01-TOOL-05
F&T Portal
Call Identifier
HORIZON-HLTH-2026-01
Call 01 — single stage (2026)
Instrument
HORIZON-IA
Innovation Action
Budget Model
Lump Sum
HORIZON-AG-LS
Funding Rate
70%
Annex G — IA = 70% (100% non-profit)
Page Limit (Part B)
45 pages
IA + lump sum (Annex A)
Evaluation Thresholds
4 / 4 / 4 · cum. 12
Non-standard — topic override
Expected Projects
4
€6–8M per project (WP stated)
Destination
Developing and using new tools, technologies and digital solutions for a healthy society
WP Part 4
Cluster / Pillar
Cluster 1 / Pillar II
Health
China Eligibility
Excluded ⚠
IA China control restriction
Special Conditions
Prior HE project required ⚠
Must build on completed H2020/HE project
Chinese entities are excluded from IA actions under this destination. Entities established in an eligible country but controlled by China are not eligible to participate in this Innovation Action in critical technology areas.
Prior project requirement: Proposals must be based on results from a completed multi-beneficiary project funded under H2020 or Horizon Europe (max 3 years before submission deadline). MSCA-funded projects are not eligible. Ongoing projects are not eligible.
This topic uses non-standard evaluation thresholds: 4 (Excellence) / 4 (Impact) / 4 (Implementation), cumulative 12. Standard thresholds are 3/3/3 cumulative 10.
US entities eligible: In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, legal entities established in the United States of America are eligible to receive Union funding under this topic.
Copernicus/Galileo: If the project uses satellite-based earth observation, positioning, navigation and/or related timing data, beneficiaries must make use of Copernicus and/or Galileo/EGNOS.
Mandatory annex: Proposals under this topic are expected to include clinical studies. Applicants should provide details in the dedicated annex using the template provided in the submission system.
Expected Outcomes
- The overall competitiveness of the EU biotechnology sector is strengthened through the further development of closer-to-deployment health innovations.
- The EU benefits from greater impact of the EU’s Research and Innovation (R&I) Framework Programmes through successful leveraging of previous EU funding in the field of regenerative medicine.
- EU innovators secure further funding to finalise the last stages of development.
- Patients benefit faster from solutions that improve their health and wellbeing.
Want the full analysis?
The key facts above tell you WHAT. The full Decision Brief tells you HOW to win.
Compliance traps
Scoring playbook
Consortium blueprint
Positioning guide
Red flags
Quick-start checklist
Order Full Brief — €79
Delivered within 1 working day